Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Retinoids - Important Safety Information from Roche Products (Ireland) Ltd, Mylan Healthcare Ltd, Teva Pharmaceuticals Ireland, Galderma (UK) Ltd and Eisai Ltd as approved by the HPRA
Notice type:
3rd Party Publications
Date:
11/12/2018
Problem Or Issue:
Important Safety Information communication from Roche Products (Ireland) Ltd, Mylan Healthcare Ltd, Teva Pharmaceuticals Ireland, Galderma (UK) Ltd and Eisai Ltd: Retinoids (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin and Tazarotene) - update on teratogenicity and neuropsychiatric disorders.
Important Safety Information - Retinoids
« Back
Date Printed: 25/04/2024